Aura Biosciences: Funding, Investors & Team (Sep 2026)
Aura Biosciences is a biotech company in the clinical stage that is working on developing a type of therapy called virus-like drug conjugates (VDC) for various types of cancer. Our purpose at Aura is to make a significant difference in the treatment of cancer types with a high unmet need. We are motivated by our dedication to science and the patients who rely on us to create these new treatments. Currently, we are focusing on using our VDC technology to treat tumors in ocular and urologic oncology that have limited treatment options. Our first VDC candidate, belzupacap sarotalocan (bel-sar), is being developed as a first-line treatment for early-stage choroidal melanoma, a rare form of cancer that currently has no approved medications. In addition to this, we are also exploring the use of bel-sar for other ocular oncology indications, such as choroidal metastasis. Additionally, we have initiated a clinical program for non-muscle invasive bladder cancer (NMIBC), which is our first attempt at treating solid tumors outside of the ocular field. We are able to target a broad range of tumors with our VDCs, making them a versatile therapeutic option.
Aura Biosciences has raised $553M across 5 funding rounds on record, the most recent an undisclosed round of $299M announced in May 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aura Biosciences Company Profile and Key Stats
Latest funding round on record: May 2026.
Aura Biosciences Funding Rounds
1 of 5 rounds was announced without a disclosed amount and is excluded from the total.
Aura Biosciences raised $80.0M in an undisclosed round announced in Mar 2021.
8 months later, a Series B was announced in Nov 2021 with no disclosed amount.
2 years later, an undisclosed round of $99.0M was announced in Nov 2023.
1.5 years later, an undisclosed round of $75.0M was announced in May 2025.
1 years later, an undisclosed round of $299M was announced in May 2026.
Aura Biosciences Founders and Leadership Team
Contact details for the Aura Biosciences team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Aura Biosciences Funding Compared to Other Biotechnology Startups
Aura Biosciences' latest round of $299M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aura Biosciences in Biotechnology and Cambridge
Companies Similar to Aura Biosciences
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Aura Biosciences Funding FAQs
What does Aura Biosciences do?
Aura Biosciences is a biotech company in the clinical stage that is working on developing a type of therapy called virus-like drug conjugates (VDC) for various types of cancer. Our purpose at Aura is to make a significant difference in the treatment of cancer types with a high unmet need. We are motivated by our dedication to science and the patients who rely on us to create these new treatments. Currently, we are focusing on using our VDC technology to treat tumors in ocular and urologic oncology that have limited treatment options. Our first VDC candidate, belzupacap sarotalocan (bel-sar), is being developed as a first-line treatment for early-stage choroidal melanoma, a rare form of cancer that currently has no approved medications. In addition to this, we are also exploring the use of bel-sar for other ocular oncology indications, such as choroidal metastasis. Additionally, we have initiated a clinical program for non-muscle invasive bladder cancer (NMIBC), which is our first attempt at treating solid tumors outside of the ocular field. We are able to target a broad range of tumors with our VDCs, making them a versatile therapeutic option.
How much funding has Aura Biosciences raised?
Aura Biosciences has raised $553M across 5 rounds on record. The most recent is an undisclosed round of $299M announced in May 2026.
When did Aura Biosciences last raise funding?
Aura Biosciences' most recent funding round on record is an undisclosed round of $299M, announced in May 2026.
Who founded Aura Biosciences?
FundedIQ lists Elisabet De (Founder) at Aura Biosciences.
Who is the CEO of Aura Biosciences?
Elisabet de los Pinos is listed as CEO at Aura Biosciences.
Where is Aura Biosciences headquartered?
Aura Biosciences is based in Cambridge, Massachusetts, United States.
How many employees does Aura Biosciences have?
Aura Biosciences is in the 51-100 employee band.
How does Aura Biosciences' funding compare to other Biotechnology startups?
Aura Biosciences' latest round of $299M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Aura Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aura Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.